Oncopeptides

Oncopeptides AB is a privately held clinical stage company developing melflufen, a peptidase potentiated therapy for multiple myeloma.

Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015. Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Melflufen is a very potent anti-angiogenetic compound, triggers rapid, robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA. Melflufen is currently undergoing Phase 2 efficacy studies in patients with relapsed and relapsed-refractory multiple myeloma. The peptidase targeting causes melflufen and its metabolites to accumulate in the diseased cells. This results in targeted delivery of the active moieties to the cancer cells, and thereby better treatment of the disease.